BOVIGEN SCOUR Emulsion for injection for cattle

Authorised

- Bovine coronavirus, strain C-197, Inactivated
- Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
- Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain EC/17, Inactivated

Product identification

Medicine name:
BOVIGEN SCOUR Emulsion for injection for cattle

Active substance:
Bovine coronavirus, strain C-197, Inactivated

Bovine rotavirus A, type G6P1, strain TM-91, Inactivated

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain EC/17, Inactivated

Target species:
Cattle

Route of administration:
Intramuscular use

Product details

Active substance and strength:

Bovine coronavirus, strain C-197, Inactivated
5.00 log2 haemagglutination inhibiting unit(s) / 1.00 Dose

Bovine rotavirus A, type G6P1, strain TM-91, Inactivated
6.00 log2 virus neutralising unit(s) / 1.00 Dose

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain EC/17, Inactivated
44.80 enzyme-linked immunosorbent assay unit / 1.00 Dose

Pharmaceutical form:
Emulsion for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cattle**
  - Meat and offal. 0 day
  - Milk. 0 hour

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI02AL01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Latvia

Available in:
Latvia

Package description:
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Forte Healthcare Limited

Marketing authorisation date:
29/09/2015

Manufacturing sites for batch release:
Pharmagal Bio spol. s r.o.

Responsible authority:
Food And Veterinary Service

Authorisation number:
V/MRP/15/0039

Date of authorisation status change:
29/09/2015

Reference member state:
Ireland

Procedure number:
IE/V/0341/001

Concerned member states:
Austria Belgium Croatia Cyprus Denmark Estonia Finland France Germany Greece Italy Latvia Lithuania Luxembourg Malta Netherlands Norway Portugal Romania Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 15/02/2026
Download

Summary of Product Characteristics